Stella Diagnostics (Stella Diagnostics) FCF Yield % : 0.00 (As of Jun. 05, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Stella Diagnostics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Stella Diagnostics's Trailing 12-Month Free Cash Flow is $0.00 Mil, and Market Cap is $20.92 Mil. Therefore, Stella Diagnostics's FCF Yield % for today is 0.00%.

The historical rank and industry rank for Stella Diagnostics's FCF Yield % or its related term are showing as below:

SLDX's FCF Yield % is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: -3.17
* Ranked among companies with meaningful FCF Yield % only.

Stella Diagnostics's FCF Margin % for the quarter that ended in Sep. 2023 was 0.00%.

Stella Diagnostics FCF Yield % Historical Data

The historical data trend for Stella Diagnostics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stella Diagnostics FCF Yield % Chart

Stella Diagnostics Annual Data

Trend

FCF Yield %

Stella Diagnostics Quarterly Data
	Sep22	Sep23
FCF Yield %	-	-

Competitive Comparison of Stella Diagnostics's FCF Yield %

For the Diagnostics & Research subindustry, Stella Diagnostics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stella Diagnostics's FCF Yield % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Stella Diagnostics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Stella Diagnostics's FCF Yield % falls into.

Stella Diagnostics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Stella Diagnostics's FCF Yield % for the fiscal year that ended in . 20 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=		/
	=	N/A%

Stella Diagnostics's annualized FCF Yield % for the quarter that ended in Sep. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	0	*	4	/	40.16
	=	0.00%

Stella Diagnostics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Stella Diagnostics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Stella Diagnostics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Stella Diagnostics (Stella Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Stella Diagnostics Inc (OTCPK:SLDX) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 West Broadway, Suite 300, Salt Lake City, UT, USA, 84104

Website

https://www.stelladx.com

Stella Diagnostics Inc is a molecular diagnostics-based organization focused on improving patient management strategies for people living with severe esophageal disease. It is developing first-line diagnostic tools that provide superior molecular information for providers as compared to the current standard screening protocols.